Comparison of pre-treatment and on-treatment patient tumor biopsies (most of which came from MSS CRC patients with a non T-cell inflamed immunophenotype prior to treatment) indicated that cibisatamab and atezolizumab combination treatment led to the increase of intra-tumor proliferating T-cells, increase of PD-1+ T-cells, upregulation of PD-L1 expression on immune cells, and reduction of CEA expressing tumor cells (56, 57), corroborating pre-clinical findings presented in the current study. Here, CD274 is linked to neoplasm.